Please login to the form below
Joint Committee on Vaccination and Immunisation
This page shows the latest Joint Committee on Vaccination and Immunisation news and features for those working in and with pharma, biotech and healthcare.
JCVI recommends spring COVID-19 booster for those at highest risk
The Joint Committee on Vaccination and Immunisation (JCVI) has advised the UK government that those at the highest risk of severe COVID-19 should be offered an extra booster vaccination this ... Professor Wei Shen Lim, chair of the JCVI’s COVID-19
Latest news
-
NHS urges people yet to receive their COVID-19 booster to come forward
risk of severe COVID-19 will be able to receive a booster, following updated advice from the UK’s Joint Committee on Vaccination and Immunisation (JCVI). ... Professor Wei Shen Lim, chair of COVID-19 vaccination on the JCVI, said: "The COVID-19
-
JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
The Joint Committee on Vaccination and Immunisation (JCVI) has advised the UK government that those at a higher risk of severe COVID-19 should be offered a booster vaccination this autumn. ... Professor Wei Shen Lim, chair of COVID-19 vaccination on the
-
NHS to move ahead with Pfizer/BioNTech bivalent COVID-19 vaccine roll-out
UK health secretary Steve Barclay to accept the guidance of the Joint Committee on Vaccination and Immunisation (JCVI). ... The Committee for Medicinal Products for Human Use – a branch of the European Medicine Agency – recently recommended the
-
Novavax’s COVID-19 vaccine candidate approved by MHRA for adolescents aged 12 to 17
The next step for the vaccine is a policy recommendation for use from the UK Joint Committee on Vaccination and Immunisation (JCVI). ... Commenting on the MHRA’s decision, Stanley Erck, president and chief executive officer, Novavax, said: "As we start
-
JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign
The Joint Committee on Vaccination and Immunisation (JCVI) has published its advice on which COVID-19 vaccines should be used in this year’s autumn booster programme. ... Professor Wei Shen Lim, chair of COVID-19 immunisation on the JCVI, said: "All of
More from news
Approximately 5 fully matching, plus 26 partially matching documents found.
Latest from PMHub
-
The UK has approved the first vaccine for COVID-19. What now?
by Glen Halliwell, Business Unit Director, Langland. The Joint Committee on Vaccination and Immunisation has quickly answered the first question regarding the priority vaccination groups for phase one. ... hesitation. The challenge of rolling out a brand
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
